Christopher Liu
Stock Analyst at LUCID CAPITAL MARKETS
(2.02)
# 3,029
Out of 4,960 analysts
6
Total ratings
33.33%
Success rate
13.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GNLX Genelux | Initiates: Buy | $10 | $3.78 | +164.55% | 1 | Jul 21, 2025 | |
| RLAY Relay Therapeutics | Maintains: Outperform | $19 → $18 | $3.69 | +387.80% | 1 | Dec 4, 2024 | |
| IDYA IDEAYA Biosciences | Downgrades: Market Perform | $41 → $27 | $25.12 | +7.48% | 2 | Nov 5, 2024 | |
| NUVL Nuvalent | Initiates: Market Perform | $42 | $76.08 | -44.79% | 1 | Aug 8, 2023 | |
| EXEL Exelixis | Initiates: Market Perform | $18 | $38.63 | -53.40% | 1 | Aug 8, 2023 |
Genelux
Jul 21, 2025
Initiates: Buy
Price Target: $10
Current: $3.78
Upside: +164.55%
Relay Therapeutics
Dec 4, 2024
Maintains: Outperform
Price Target: $19 → $18
Current: $3.69
Upside: +387.80%
IDEAYA Biosciences
Nov 5, 2024
Downgrades: Market Perform
Price Target: $41 → $27
Current: $25.12
Upside: +7.48%
Nuvalent
Aug 8, 2023
Initiates: Market Perform
Price Target: $42
Current: $76.08
Upside: -44.79%
Exelixis
Aug 8, 2023
Initiates: Market Perform
Price Target: $18
Current: $38.63
Upside: -53.40%